Decheng Capital LLC
Annual return '25
+17.0%
SPY '25
+17.7%
Alpha
-0.7ptsvs SPY
Invested
$661.3M
Holdings
13
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 99%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$CGON
CG ONCOLOGY INC
Q1 2026: Exited (was 6.37M shares)
66.6%
02
$NUVB
Nuvation Bio Inc.
Q1 2026: Exited (was 25.95M shares)
17.2%
03
$UPB
Upstream Bio Inc.
Q1 2026: Exited (was 3.14M shares)
3.8%
04
$ACRS
Aclaris Therapeutics, Inc.
Q1 2026: Exited (was 4.04M shares)
2.3%
05
$AARD
AARDVARK THERAPEUTICS INC
Q1 2026: Exited (was 3.92M shares)
2.3%
06
$NAMS
NEWAMSTERDAM PHARMA CO NV
Q1 2026: Exited (was 592.1k shares)
1.6%
07
$RCUS
Arcus Biosciences, Inc
Q1 2026: Exited (was 541.6k shares)
1.6%
08
$RVMD
REVOLUTION MEDICINES INC(NSM)
Q1 2026: Exited (was 200.0k shares)
1.4%
09
$EQ
Equillium Inc.
Q1 2026: Exited (was 4.45M shares)
1.4%
10
$BYSI
BeyondSpring Inc.
Q1 2026: Exited (was 3.80M shares)
1.0%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 08:05 UTC.